Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 3/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | WNK1 | Q9H4A3 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL517109 | 1.00 | LMNA (0.50) | LMNAMEN1KMT2AMAPTL3MBTL1 | |
| SCHEMBL517081 | 0.82 | VCAM1 (0.46) | LMNAMEN1KMT2AMAPTPKM | |
| SCHEMBL517082 | 0.82 | VCAM1 (0.46) | LMNAMEN1KMT2AMAPTPKM | |
| SCHEMBL15793149 | 0.74 | GNRHR (0.48) | MEN1KMT2AL3MBTL1TP53SMN1; SMN2 | |
| SCHEMBL516685 | 0.74 | CA1 (0.40) | LMNAKMT2ATDP1HTT | |
| SCHEMBL516684 | 0.74 | CA1 (0.40) | LMNAKMT2ATDP1HTT | |
| SCHEMBL516920 | 0.73 | MAPT (0.53) | LMNAMEN1KMT2AMAPTL3MBTL1 | |
| SCHEMBL516919 | 0.73 | MAPT (0.53) | LMNAMEN1KMT2AMAPTL3MBTL1 | |
| SCHEMBL10269830 | 0.72 | MAPK1 (0.41) | LMNAMEN1KMT2AMAPTPKM | |
| SCHEMBL15793658 | 0.70 | IDH2 (0.43) | HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9789118-B2 | Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof | NOVARTIS AG (CH) | 2017-10-17 | — | — | US | disclosed |
| US-9789118-B2 | Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof | NOVARTIS AG (CH) | 2017-10-17 | — | — | US | disclosed |
| US-9789118-B2 | Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof | NOVARTIS AG (CH) | 2017-10-17 | — | — | US | disclosed |
| US-20140171363-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2014-06-19 | — | — | US | disclosed |
| US-20140171363-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2014-06-19 | — | — | US | disclosed |
| US-20140171363-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2014-06-19 | — | — | US | disclosed |
| US-8697739-B2 | Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof | NOVARTIS AG (CH) | 2014-04-15 | — | — | US | disclosed |
| US-20120028969-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2012-02-02 | — | — | US | disclosed |
| US-20120028969-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2012-02-02 | — | — | US | disclosed |
| US-20120028969-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2012-02-02 | — | — | US | disclosed |
| WO-2012013716-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS | NOVARTIS AG (CH) | 2012-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140171363-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF | ACACA, ACACB, COASY | LMNA 2697/4885MEN1 3950/4885KMT2A 2537/4885 |
| US-20120028969-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF | ACACA, ACACB, COASY | LMNA 2697/4885MEN1 3950/4885KMT2A 2537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.